Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Electrolyte and fluid replacement; dextrose provides caloric support.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Fluid and electrolyte replenishment,Correction of metabolic acidosis,Intravenous source of calories
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable; components are endogenous substances. Dextrose has a plasma half-life of approximately 1.5-2.5 hours in normal glucose metabolism; electrolytes have half-lives dependent on renal function (e.g., sodium half-life ~1-2 days).
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are absorbed and excreted by the kidneys.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal excretion of water and electrolytes; dextrose is metabolized to CO2 and water. >90% of water and electrolytes are excreted renally; dextrose is fully metabolized.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Minimal (<5%); electrolytes are not significantly protein-bound; dextrose does not bind to proteins.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Electrolytes distribute to total body water (~0.6 L/kg); dextrose distributes to extracellular fluid initially (~0.2 L/kg) then intracellularly.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100% bioavailability.
100% intravenous; not administered by other routes.
No specific dose adjustment; monitor fluid and electrolyte status closely in renal impairment due to risk of volume overload and electrolyte disturbances.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific dose adjustment; monitor for fluid overload and electrolyte imbalances due to potential altered metabolism.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Intravenous infusion; rate based on weight: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, and 20 m L/kg/day for each kg above 20 kg.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution; consider lower infusion rates due to decreased renal function and risk of fluid overload; monitor electrolytes and renal function closely.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
Not for use in patients with hyperglycemia or certain electrolyte imbalances; solutions containing aluminum may be toxic with prolonged use in renally impaired patients.
Not applicable; no FDA boxed warning exists for this product.
Monitor serum electrolytes, fluid balance, blood glucose; risk of hyperglycemia, hypokalemia, fluid overload; avoid in patients with renal impairment or heart failure.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hyperkalemia, hypernatremia, hyperglycemia, severe metabolic acidosis, anuria, or hypersensitivity to any component.
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No direct food interactions. However, dietary intake of electrolytes (e.g., potassium, sodium) should be considered in patients receiving this solution. Avoid high-potassium foods if hyperkalemia is a concern.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/third trimester: use as needed for fluid/electrolyte balance. Dextrose may cause maternal hyperglycemia, which can affect fetal glucose and insulin levels, potentially leading to fetal hyperinsulinism and neonatal hypoglycemia if maternal glucose is poorly controlled.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Isolyte R in Dextrose 5% components (dextrose, electrolytes) are normal constituents of breast milk. No known adverse effects. M/P ratio not applicable as dextrose and electrolytes are endogenous substances. Use is considered compatible with breastfeeding.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No specific dose adjustments required for pregnancy. However, due to increased plasma volume and glomerular filtration rate in pregnancy, individualize based on fluid and electrolyte needs. Monitor for hyperglycemia, which may require dose reduction or insulin therapy. Use caution in preeclampsia or impaired renal function.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
ISOLYTE R in Dextrose 5% is an isotonic solution used for fluid and electrolyte replacement. Monitor serum glucose and electrolytes, especially in diabetic patients. Avoid in patients with hyperglycemia, hyperkalemia, or hyperlactatemia. Use with caution in renal impairment. The solution contains 130 m Eq/L sodium, 4 m Eq/L potassium, 3 m Eq/L calcium, 1 m Eq/L magnesium, 109 m Eq/L chloride, 28 m Eq/L lactate, and 5% dextrose. It provides 170 kcal/L. Do not administer simultaneously with blood products through same line.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
Inform your healthcare provider if you have diabetes, kidney problems, or heart failure.,Report any signs of fluid overload (swelling, difficulty breathing) or electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,This solution contains sugar; monitor blood glucose if you have diabetes.,Do not use if the solution is cloudy or contains particles.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Electrolyte and fluid replacement; dextrose provides caloric support.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/th. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.